Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study

BACKGROUND: Everolimus (EVE) is an inhibitor of the mammalian target of rapamycin (mTOR) pathway, and it is approved for the treatment of advanced breast cancer (ABC). However, there is still little real-world data on using EVE in Chinese breast cancer patients. We retrospectively analyzed real-worl...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Xia-Bo, Li, Guang-Liang, Zheng, Ya-Bing, Chen, Zhan-Hong, Cao, Wen-Ming, Wang, Xiao-Jia, Shao, Xi-Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422157/
https://www.ncbi.nlm.nih.gov/pubmed/34532471
http://dx.doi.org/10.21037/atm-21-3840

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422157/
https://www.ncbi.nlm.nih.gov/pubmed/34532471
http://dx.doi.org/10.21037/atm-21-3840

Ejemplares similares